News / Partnerships / Press Releases - December 8, 2022
A new initiative to boost research and development into rare and paediatric diseases will launch today [Thursday 8 December] at the European Health Summit. The ‘Rare Disease Moonshot’ is a commitment and collaboration between seven organisations to break down the barriers to finding new treatments and cures… read more
Member Spotlight / News - November 30, 2022
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In October, we spoke with Óscar Perez, Chief Officer, Marketing, Pricing & Market Access and Business Development at Ferrer Internacional…. read more
EUCOPE Resources / Events & Meetings - October 3, 2022
On September 5, 2022, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and Bundesverband der Pharmazeutischen Industrie (BPI) organised an online event on the revision of the EU regulatory framework for orphan drugs and its impact on Germany. The upcoming revision was discussed together with patient… read more
News - May 10, 2022
This article originally featured in PharmaBoardroom. You can find the original article here. EUCOPE’s Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new procedure leads… read more
Member Spotlight / News - May 6, 2022
Every month, EUCOPE spotlights a member company and the great work they’re doing to advance the life sciences industry and drive innovation to serve patients better. In April, we spoke with Malte Peters, M.D., Chief Research and Development Officer, MorphoSys. Dr. Malte Peters joined MorphoSys in… read more
EUCOPE Resources / News / Press Releases - July 29, 2021
The European Commission is consulting stakeholders as part of its revision process of two major pieces of legislation, on medicines for rare diseases and paediatric patients. Central to the development of innovative treatments for these specific categories of patients, this revision process represents an important… read more
EUCOPE Resources - July 8, 2021
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
News / Press Releases - June 11, 2021
The multidisciplinary European Expert Group on Orphan Drug Incentives (OD Expert Group) has developed fourteen innovative proposals along the entire lifecycle of orphan drug development to address the unmet needs in rare diseases. With over ninety percent of patients without a centrally approved treatment option,… read more
News - April 26, 2021
On 7 May, the European Commission opened its public consultation on the revision of EU rules on medicines for children and rare diseases. The consultation, aimed at stakeholders and members of the general public, including patients and doctors, will explore several options to address the shortcomings… read more
News - February 26, 2021
Last January, the European Commission launched the consultation on the European Health Emergency Preparedness and Response Authority, HERA for short. How can we make sure this new agency finds its way? Clarity on its roles and responsibilities will be needed. See our take in this… read more
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information